App-Quantinova.ai

LuCa-MERIT-1: First-in-human open label dose confirmation trial evaluating safety, tolerability, and efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

Patrick Forde - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Gastric cancer in a post pancreaticoduodenectomy patient with ATM mutation – interesting case

I. Siddiqui - International Hepato-Pancreato-Biliary Association (IHPBA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

REPURPOSING CHEMOTHERAPIES AGAINST HIGH-RISK MENINGIOMAS WITH GUIDANCE BY METHYLATION PROFILES

Anh Tran - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Meningiomas

Docetaxel

DOCETAXEL TARGETS AGGRESSIVE METHYLATION PROFILES AND SERVES AS A RADIOSENSITIZER IN HIGH-RISK MENINGIOMAS

Mark Youngblood - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Docetaxel

ACTIVATION OF GABAA RECEPTORS WITH A NON-TOXIC, BRAIN PENETRANT SMALL MOLECULE SENSITIZES LUNG ADENOCARCINOMA PRIMARY AND BRAIN METASTATIC TUMOR CELLS TO RADIATION VIA AUTOPHAGY INDUCTION

Debanjan Bhattacharya - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Analysis of the prevalence of fusion oncogenes in cutaneous angiosarcoma

M. Jinnin - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Infantile hepatic hemangioma

Docetaxel

The microbial flora of taxane therapy-associated nail disease in cancer patients

C.A. Virgen - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Eribulin has anti-tumor activity in a preclinical model of merkel cell carcinoma

K. Miyamoto - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Merkel cell carcinoma

Docetaxel

Modified GTX second-line therapy in pancreatic adenocarcinoma: An updated analysis

M. Mezher - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Metastatic pancreatic adenocarcinoma

Docetaxel

Different regimens of the 1st line chemotherapy in patients (pts) with metastatic anal cancer: Results of the multicenter observational study

M. Fedyanin - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Docetaxel

A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

T. Ando - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

Real-world delivery, toxicity and outcomes of perioperative FLOT chemotherapy in resectable gastric/gastroesophageal adenocarcinoma: A population-based study

E. Di Gravio - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Docetaxel

Impact of death-associated protein-3 (DAP3) and DAP3 binding cell death enhancer 1 (DELE1) on drug sensitivity in colorectal cancer cells

L. Sui - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Docetaxel

Real-world data of perioperative FLOT in resectable gastric and gastro-esophagic junction cancer: The experience of a Portuguese institution

M. Vilas-Boas - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Chemotherapy induced neuropathic pain. Clinical diagnosis and treatment

A Vadalouca - European Society of Regional Anaesthesia & Pain Therapy (ESRA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Peripheral neuropathy

Docetaxel

Sarcoma regimens for gynecologic carcinosarcoma: Is there a benefit?

Gabriela Betancourt - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ovarian carcinosarcoma

Docetaxel

Primary Cardiac Angiosarcoma: A Rare Cause of Dyspnea

S. Farooq - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Dyspnea

Docetaxel

Prevention of Docetaxel (Doc)-Induced Neutropenia (DIN) with Single Agent Plinabulin (Plin) Versus (vs) Control (No-Treatment or Placebo) in Non-Small Cell Lung Cancer (NSCLC) in Two Randomized Trials

Douglas W. Blayney - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

A Bioinformatic Approach to the Clinical Evaluation of Linear Commitment Versus Cloud (Continuum of Low Primed UnDifferentiated) Models for Hematopoiesis Using Plinabulin Clinical Trial Data

Ramon W. Mohanlal - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Neutropenia

Docetaxel

Filters

2459 Abstracts